Home > Boards > US Listed > Biotechs > Portola Phramaceuticals (PTLA)

Submits PAS for broad Andexxa commercial launch

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
H2R Member Profile
 
Followed By 14
Posts 1,459
Boards Moderated 0
Alias Born 07/17/14
160x600 placeholder
Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019 PR Newswire (US) - 10/15/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 4:21:37 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 10/2/2019 4:17:31 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/23/2019 6:33:32 AM
Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors PR Newswire (US) - 9/19/2019 8:20:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/5/2019 7:06:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/5/2019 7:03:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2019 6:05:36 PM
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences PR Newswire (US) - 8/22/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/14/2019 4:20:36 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/14/2019 4:15:44 PM
Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire (US) - 8/13/2019 7:32:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/12/2019 4:46:55 PM
Portola Pharmaceuticals Announces Proposed Offering of Common Stock PR Newswire (US) - 8/12/2019 4:43:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/9/2019 6:51:55 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/7/2019 5:16:00 PM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 8/7/2019 5:12:36 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:32:57 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/7/2019 4:13:13 PM
Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update PR Newswire (US) - 8/7/2019 4:05:00 PM
Portola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in Europe PR Newswire (US) - 8/6/2019 8:30:00 AM
U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portol... PR Newswire (US) - 8/5/2019 7:00:00 AM
Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019 PR Newswire (US) - 7/17/2019 8:30:00 AM
Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) ... PR Newswire (US) - 7/8/2019 8:30:00 AM
Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Re... PR Newswire (US) - 6/19/2019 11:05:00 AM
H2R   Friday, 08/31/18 09:52:28 AM
Re: None
Post # of 182 
Submits PAS for broad Andexxa commercial launch

http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsroomArticle&ID=2365666

Quote:
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the submission of a prior approval supplement (PAS) to the U.S. Food and Drug Administration (FDA) for the large-scale Generation 2 manufacturing process for Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo]. If approved, the PAS will allow for broad commercial launch of Andexxa in the United States.

Andexxa received both U.S. Orphan Drug and FDA Breakthrough Therapy designations, and was approved on May 3, 2018 under the FDA's Accelerated Approval pathway. It is the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

“We are pleased that patients are already benefitting from access to our limited supply Generation 1 product via an Early Supply Program,” said John Curnutte, M.D., Ph.D., interim co-president of Portola and head of research and development. “With the recent completion of three successful Generation 2 manufacturing campaigns, we have enough supply to stock more than 1,000 hospitals, and we look forward to working with regulatory authorities to achieve our goal of expanding patient access to this potentially life-saving medicine.”

Based on FDA timelines, the Company expects a final decision on the PAS in Q1 2019. In Europe, andexanet alfa received a positive trend vote from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency in February 2018. Pending the submission of additional data requested by the CHMP, a final CHMP opinion is expected in Q4 2018 with the potential for approval in Q1 2019.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist